Dynavax Technologies Co. (DVAX) VP Sells $57,511.20 in Stock
Dynavax Technologies Co. (NASDAQ:DVAX) VP David Louis Johnson sold 3,092 shares of the business’s stock in a transaction dated Thursday, January 4th. The stock was sold at an average price of $18.60, for a total value of $57,511.20. Following the sale, the vice president now owns 7,780 shares of the company’s stock, valued at approximately $144,708. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Dynavax Technologies Co. (NASDAQ:DVAX) opened at $18.50 on Monday. The company has a market capitalization of $1,121.03, a P/E ratio of -9.49 and a beta of 1.31. Dynavax Technologies Co. has a 52-week low of $3.70 and a 52-week high of $24.45.
Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.15. The firm had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.28 million. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. Dynavax Technologies’s revenue for the quarter was down 68.8% on a year-over-year basis. During the same period in the previous year, the company posted ($0.90) EPS. research analysts anticipate that Dynavax Technologies Co. will post -1.72 EPS for the current year.
A number of analysts have recently issued reports on the company. ValuEngine cut Dynavax Technologies from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Royal Bank of Canada reiterated an “outperform” rating and set a $28.00 target price (up previously from $26.00) on shares of Dynavax Technologies in a report on Monday, September 25th. BidaskClub cut Dynavax Technologies from a “buy” rating to a “hold” rating in a report on Wednesday, December 6th. Cantor Fitzgerald boosted their target price on Dynavax Technologies from $24.00 to $25.00 and gave the stock an “overweight” rating in a report on Thursday, November 9th. Finally, Cowen reiterated a “buy” rating and set a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $25.17.
A number of institutional investors have recently added to or reduced their stakes in DVAX. Russell Investments Group Ltd. lifted its position in Dynavax Technologies by 24.0% during the 2nd quarter. Russell Investments Group Ltd. now owns 155,095 shares of the biopharmaceutical company’s stock worth $1,496,000 after acquiring an additional 30,036 shares in the last quarter. Schwab Charles Investment Management Inc. lifted its position in Dynavax Technologies by 77.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 181,161 shares of the biopharmaceutical company’s stock worth $1,749,000 after acquiring an additional 79,141 shares in the last quarter. Rhumbline Advisers lifted its position in Dynavax Technologies by 35.5% during the 2nd quarter. Rhumbline Advisers now owns 60,503 shares of the biopharmaceutical company’s stock worth $584,000 after acquiring an additional 15,865 shares in the last quarter. State of Wisconsin Investment Board acquired a new position in Dynavax Technologies during the 2nd quarter worth approximately $328,000. Finally, Bank of New York Mellon Corp lifted its position in Dynavax Technologies by 41.7% during the 2nd quarter. Bank of New York Mellon Corp now owns 250,862 shares of the biopharmaceutical company’s stock worth $2,421,000 after acquiring an additional 73,866 shares in the last quarter. 70.54% of the stock is currently owned by hedge funds and other institutional investors.
Dynavax Technologies Company Profile
Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with Analyst Ratings Network's FREE daily email newsletter.